news
NICE recommends avelumab and axitinib to treat renal cell carcinoma
Bavencio (avelumab) and Inlyta (axitinib) are recommended by NICE for the treatment of advanced renal cell carcinoma, available on the Cancer Drugs Fund.
List view / Grid view
Anti-Cancer Therapeutics
news
NICE recommends Adcetris (brentuximab vedotin) for treatment of rare lymphoma
The recommendation of Adcetris (brentuximab vedotin) represents the first new frontline therapy for systemic anaplastic large cell lymphoma (sALCL) in several decades.
news
Cervical dysplasia treatment device approved for global Phase III trial
The cervical dysplasia drug-device product, APL-1702 (Cevira®), offers an alternative to surgery and has been approved to start a clinical trial in China and several other countries.
news
FDA approves new administration route for Phesgo to treat breast cancer
The FDA has given approval to Phesgo for injection under the skin to treat HER2-positive breast cancer, meaning it can be administered at home by a healthcare professional.
news
Ruxolitinib to be studied as COVID-19 treatment in clinical trial
Following the successful treatment of a COVID-19 patient with ARDS using ruxolitinib, Germany is set to begin clinical trials to test the drug.
article
Radical innovation occurs when pharma looks outside its own world
Pharma executives are committed to bringing drugs to market to improve the lives of patients but is the industry too introspective to be truly innovative?
news
NICE recommends Rozlytrek (entrectinib) as treatment for NSCLC
After three clinical trials showing its efficacy, NICE has recommended Rozlytrek (entrectinib) as treatment for non-small cell lung cancer (NSCLC).
news
Potential cytokine storm treatment identified for severe COVID-19 patients
Treating COVID-19 patients with respiratory distress with acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor reduced inflammation and improved their breathing within three days.
article
Anti-cancer drug delivery: peptoid-coated DNA origami
Scientists have designed and synthesised chains of molecules for the purpose of drug delivery with a precise sequence and length to protect DNA nanostructures from degradation under biomedically relevant conditions.
news
Dose-adjusted chemotherapy regimen effective in Burkitt lymphoma trial
Researchers reveal dose-adjusted (DA) EPOCH-R chemotherapy regimen was effective across all ages of Burkitt lymphoma patients in a Phase II clinical trial.
news
FDA approves Lynparza (olaparib) for HRR mutated prostate cancer
Lynparza’s approval was based on results from a Phase III clinical trial in which it improved overall survival and progression-free survival in patients with certain prostate cancers.
news
FDA approves Tabrecta for treatment of metastatic non-small cell lung cancer
The FDA has approved Tabrecta (capmatinib) for patients with metastatic non-small cell lung cancer whose tumours have a mutation that leads to MET exon 14 skipping.
news
Attenuated diptheria toxin developed by researchers as novel form of drug delivery
A new potential platform for drug delivery has been created by researchers using attentuate diptheria toxin, which can enter cells and escape the endosome.
news
Novel antibody delivery method could improve precision medicine
Scientists have developed a protocol for encapsulating antibodies in an ultrasound-sensitive drug carrier for targeted drug delivery.
news
NICE recommends Vitrakvi (larotrectinib) for use on Cancer Drugs Fund
Larotrectinib has been given a positive opinion by NICE, following the submission of a revised price after it was previously rejected.
